AccessClosure Announces Distribution Agreement for the FLASH™ Ostial System Outstanding Device for Treatment of Ostial Disease Expands AccessClosure's Portfolio
SANTA CLARA, Calif., Oct. 8, 2013 /PRNewswire/ -- AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Ostial Corporation to distribute the Flash Ostial System Dual Balloon Angioplasty Catheter in the United States. The Flash Ostial System is designed to help overcome the challenges of aorto-ostial stenting and compliments the Mynx® Product Family of Vascular Closure Devices to expand AccessClosure's portfolio.
"AccessClosure is well-positioned to add relevant and useful products to our portfolio due to the strong relationships of our sales team with interventional cardiologists, vascular surgeons, and interventional radiologists through the sale of Mynx," said Gregory D. Casciaro, President and CEO of AccessClosure. "As a customer-focused company, we strive to provide innovative technologies such as Mynx and Flash for superb clinical outcomes. Including the Flash Ostial System in our portfolio allows AccessClosure to increase our level of service and education to healthcare providers."
Ostial lesions are a challenging area for treatment. According to Richard Kovach, M.D., Chair, Interventional Cardiology and Director, Cardiac Catheterization Laboratory at Deborah Heart and Lung Center, in Browns Mills, NJ, "The dual balloon design of the Flash Ostial System is an exciting treatment option for ostial disease. Flash conforms to the ostium to enable excellent stent apposition, which is important for coverage of the disease and for preserving reaccess to the treated vessel." Dr. Kovach has been using the Flash Ostial System in his practice for the past year.
"AccessClosure is the ideal partner to distribute the Flash device," said Yi Yang, Chief Operating Officer of Ostial Corporation. "Their sales team understands the importance of bringing innovative products to market that offer a clinical benefit."
AccessClosure will showcase its growing portfolio of devices at booth 314 at the Vascular Interventional Advances 2013 (VIVA) this week in Las Vegas, NV, beginning Tuesday when the exhibit hall opens at the Wynn Hotel.
Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative, patient-friendly products designed to address complex challenges in the cardiovascular and peripheral vascular markets. For more information, visit our website at www.accessclosure.com.
About Ostial Corporation
Ostial Corporation is a privately held Silicon Valley medical device company founded to address the unmet needs of treatment of ostial diseases of the coronary and peripheral vascular systems. For more information, visit the company's website at www.ostial.com.
SOURCE AccessClosure, Inc.